Vero, a predictive health company on a mission to end age-related chronic disease, today announced it is adding cellular resolution to its OrganAge™ platform with an exclusive consumer license to Stanford’s proteomic Cell Clock technology. Developed in the laboratory of Vero co-founder Dr. Tony Wyss-Coray, Cell Clocks measure biological aging across specific cell types, providing a deeper view into the drivers of organ aging and disease risk. By combining organ and cellular aging signals, Vero moves biological aging beyond a single score toward a clinically actionable tool that helps identify where aging is occurring, explain the biology behind it, and guide more precisely targeted interventions.

Vero’s OrganAge™ uses AI-powered proteomic Organ and Cell Clock technologies to measure biological age from a single blood test. The test is the entry point to Vero Compass™, a predictive digital health system that guides consumers and clinicians toward precision interventions designed to slow or reverse organ aging. By testing and retesting, Vero Compass creates a continuous feedback loop that demonstrates how each organ responds to interventions, empowering people to take action to extend their healthspan.

Why Proteomic Organ and Cell Aging Matters

Vero’s proteomic OrganAge is also built on technology developed at Stanford in Wyss-Coray’s laboratory and validated in studies involving more than 45,000 individuals, with landmark findings published in Nature (2023) and Nature Medicine (2025). The research showed that measuring more than 11,000 organ-specific proteomic signatures in blood plasma can reveal distinct aging rates of individual organs.

Wyss-Coray’s Cell Clock research, published in Nature Medicine (2026), extended those discoveries to the cellular level. Built on one of the largest plasma proteomic datasets to date, the study revealed unprecedented resolution into the biological mechanisms driving aging—including findings around Alzheimer’s resilience in APOE4 carriers, ALS risk detection years before symptom onset, and cellular aging patterns that predict future disease risk even in seemingly healthy individuals.

“Over the past decade, our laboratory has worked to advance our understanding of how aging unfolds across organs and cell types,” said Dr. Tony Wyss-Coray, professor of neurology and neurological sciences at Stanford and co-founder of Vero. “If Organ Clocks act like a check engine light signaling which systems are at risk, Cell Clocks effectively open the hood—moving us from detecting early signs of aging on an organ level to understanding the exact cellular mechanisms driving dysfunction. The broader implication is a shift from reactive medicine toward earlier, more precise prediction and intervention for aging and chronic disease.”

A New Era of Biological Aging

For years, biological aging relied on single “scores” or population-level metrics and provided limited guidance for personalized treatment decisions. In a recent Nature Medicine review paper (2026), Drs. Eric Topol and Tony Wyss-Coray identified proteomic aging clocks as one of the field’s most promising advances.

Enhanced with Cell Clock technology and integrated into Vero Compass, Vero’s OrganAge moves biological age testing beyond traditional measures by pinpointing organ- and cellular-level vulnerabilities to guide precision interventions and track real-time biological responses.

“Scientific discovery only changes healthcare when it reaches people,” said Paul Coletta, co-founder and CEO of Vero. “Our mission is to translate pioneering Stanford science into practical tools that help individuals understand how they’re aging, intervene earlier, and objectively measure whether those interventions are improving their health.”

Vero’s OrganAge is currently accessible through exclusive clinical research partnerships, with limited early access launching ahead of broad consumer availability in 2027. The company recently announced a research collaboration with Biograph, a preventive health and longevity clinic, to evaluate Vero OrganAge alongside Biograph’s clinical, imaging, and performance-based assessments. This is part of ongoing efforts to further validate Vero OrganAge as an established clinical biomarker of healthspan.

Vero is now opening its waitlist to grant priority access. To learn more and sign up, visit verobioscience.com.

About Vero

Vero is a predictive health company on a mission to end age-related chronic disease. Built on groundbreaking Stanford University research, Vero uses advanced proteomics and machine learning to measure the biological aging of organ systems from a simple blood test. The Vero OrganAge™ test, now enhanced with Cell Clocks™, is the entry point to Vero Compass™ – a system that translates complex biological signals into clear, actionable insights that help clinicians and individuals intervene earlier and track meaningful improvement over time. Backed by leading scientific and clinical advisors, Vero is building the next era of predictive health to empower people to prevent disease and extend healthspan. To learn more and access Vero’s research programs, visit verobioscience.com and join the waitlist. Follow Vero on LinkedIn and X.

Media gallery

About The Author
Business Wire